Tags : LIBERTY ASTHMA TRAVERSE OLE

Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA

Shots: The P-III OLE study involves assessing of Dupixent (300mg) + SOC in 2,282 adults/ adolescents with mod.-to-sev. asthma prior participated in a controlled Dupixent clinical trial, including the pivotal P-IIb DRI (24wks.) and P-III QUEST (52wks.) trials in patients with mod.-to-sev. asthma and the P-III VENTURE (24wks.) trial in patients with severe OCS-dependent asthma […]Read More